OTCMKTS:TMED

Trimedyne Competitors

$4.25
-0.01 (-0.23 %)
(As of 03/20/2020)
Add
Compare
Today's Range
$4.25
Now: $4.25
$4.25
50-Day Range
$4.25
MA: $4.25
$4.25
52-Week Range
$3.48
Now: $4.25
$7.00
Volume100 shs
Average Volume570 shs
Market Capitalization$522,750.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Trimedyne (OTCMKTS:TMED) Vs. MDT, SONVY, VAR, MASI, GNGBY, and LIVN

Should you be buying TMED stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Trimedyne, including Medtronic (MDT), Sonova (SONVY), Varian Medical Systems (VAR), Masimo (MASI), Getinge (GNGBY), and LivaNova (LIVN).

Trimedyne (OTCMKTS:TMED) and Medtronic (NYSE:MDT) are both computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Institutional & Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. 11.1% of Trimedyne shares are owned by company insiders. Comparatively, 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Trimedyne and Medtronic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trimedyne0000N/A
Medtronic031812.91

Medtronic has a consensus price target of $124.2692, indicating a potential upside of 0.30%. Given Medtronic's higher probable upside, analysts plainly believe Medtronic is more favorable than Trimedyne.

Profitability

This table compares Trimedyne and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrimedyneN/AN/AN/A
Medtronic12.69%9.71%5.30%

Earnings & Valuation

This table compares Trimedyne and Medtronic's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trimedyne$5.57 million0.09$230,000.00N/AN/A
Medtronic$28.91 billion5.78$4.79 billion$4.5926.99

Medtronic has higher revenue and earnings than Trimedyne.

Summary

Medtronic beats Trimedyne on 10 of the 11 factors compared between the two stocks.

Trimedyne (OTCMKTS:TMED) and Sonova (OTCMKTS:SONVY) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

1.1% of Sonova shares are held by institutional investors. 11.1% of Trimedyne shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Trimedyne and Sonova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trimedyne0000N/A
Sonova06302.33

Profitability

This table compares Trimedyne and Sonova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrimedyneN/AN/AN/A
SonovaN/AN/AN/A

Earnings and Valuation

This table compares Trimedyne and Sonova's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trimedyne$5.57 million0.09$230,000.00N/AN/A
Sonova$2.96 billion6.22$489.96 million$1.4938.34

Sonova has higher revenue and earnings than Trimedyne.

Summary

Sonova beats Trimedyne on 5 of the 6 factors compared between the two stocks.

Trimedyne (OTCMKTS:TMED) and Varian Medical Systems (NYSE:VAR) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. 11.1% of Trimedyne shares are held by insiders. Comparatively, 0.8% of Varian Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Trimedyne and Varian Medical Systems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trimedyne0000N/A
Varian Medical Systems35001.63

Varian Medical Systems has a consensus price target of $159.3571, indicating a potential downside of 10.04%. Given Varian Medical Systems' higher probable upside, analysts plainly believe Varian Medical Systems is more favorable than Trimedyne.

Profitability

This table compares Trimedyne and Varian Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrimedyneN/AN/AN/A
Varian Medical Systems8.50%18.45%8.08%

Earnings and Valuation

This table compares Trimedyne and Varian Medical Systems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trimedyne$5.57 million0.09$230,000.00N/AN/A
Varian Medical Systems$3.17 billion5.15$269.20 million$3.9145.40

Varian Medical Systems has higher revenue and earnings than Trimedyne.

Summary

Varian Medical Systems beats Trimedyne on 8 of the 9 factors compared between the two stocks.

Trimedyne (OTCMKTS:TMED) and Masimo (NASDAQ:MASI) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Profitability

This table compares Trimedyne and Masimo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrimedyneN/AN/AN/A
Masimo20.30%15.75%13.12%

Institutional and Insider Ownership

81.6% of Masimo shares are held by institutional investors. 11.1% of Trimedyne shares are held by insiders. Comparatively, 11.5% of Masimo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Trimedyne and Masimo, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trimedyne0000N/A
Masimo02502.71

Masimo has a consensus price target of $272.20, indicating a potential upside of 13.67%. Given Masimo's higher probable upside, analysts plainly believe Masimo is more favorable than Trimedyne.

Earnings and Valuation

This table compares Trimedyne and Masimo's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trimedyne$5.57 million0.09$230,000.00N/AN/A
Masimo$937.84 million14.11$196.22 million$3.2274.37

Masimo has higher revenue and earnings than Trimedyne.

Summary

Masimo beats Trimedyne on 10 of the 10 factors compared between the two stocks.

Trimedyne (OTCMKTS:TMED) and Getinge (OTCMKTS:GNGBY) are both computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Trimedyne and Getinge's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrimedyneN/AN/AN/A
Getinge10.51%17.30%7.90%

Institutional and Insider Ownership

0.0% of Getinge shares are owned by institutional investors. 11.1% of Trimedyne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Trimedyne and Getinge's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trimedyne$5.57 million0.09$230,000.00N/AN/A
Getinge$2.81 billion2.70$129.29 millionN/AN/A

Getinge has higher revenue and earnings than Trimedyne.

Analyst Recommendations

This is a breakdown of current ratings for Trimedyne and Getinge, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trimedyne0000N/A
Getinge11502.57

Summary

Getinge beats Trimedyne on 8 of the 9 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Trimedyne (OTCMKTS:TMED) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Institutional and Insider Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by insiders. Comparatively, 11.1% of Trimedyne shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for LivaNova and Trimedyne, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova04202.33
Trimedyne0000N/A

LivaNova currently has a consensus price target of $69.3333, indicating a potential downside of 14.83%. Given LivaNova's higher possible upside, equities research analysts plainly believe LivaNova is more favorable than Trimedyne.

Profitability

This table compares LivaNova and Trimedyne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
TrimedyneN/AN/AN/A

Valuation & Earnings

This table compares LivaNova and Trimedyne's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.65$-155,180,000.00$3.0826.43
Trimedyne$5.57 million0.09$230,000.00N/AN/A

Trimedyne has lower revenue, but higher earnings than LivaNova.

Summary

LivaNova beats Trimedyne on 7 of the 10 factors compared between the two stocks.


Trimedyne Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.7$123.90-0.2%$166.66 billion$28.91 billion47.29
Sonova logo
SONVY
Sonova
0.9$57.13-1.5%$18.40 billion$2.96 billion38.34Increase in Short Interest
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.52-0.2%$16.27 billion$3.17 billion60.59
Masimo logo
MASI
Masimo
1.6$239.46-0.1%$13.22 billion$937.84 million62.20Insider Selling
Getinge logo
GNGBY
Getinge
0.6$29.83-0.0%$7.58 billion$2.81 billion24.65Upcoming Earnings
Analyst Upgrade
News Coverage
LivaNova logo
LIVN
LivaNova
1.5$81.41-0.8%$3.99 billion$1.08 billion-18.93Analyst Report
News Coverage
CNMD
CONMED
1.6$130.42-1.1%$3.82 billion$955.10 million-3,260.50
InMode logo
INMD
InMode
1.5$84.02-0.2%$2.68 billion$156.36 million60.45Analyst Downgrade
Outset Medical logo
OM
Outset Medical
1.0$54.58-0.1%$2.34 billionN/A0.00Analyst Upgrade
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$33.63-3.0%$1.16 billion$27.37 million-46.07Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$28.66-4.6%$926.45 million$495.52 million-52.11
AxoGen logo
AXGN
AxoGen
1.5$19.40-1.3%$801.17 million$106.71 million-30.79News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$29.12-0.6%$792.09 million$23.60 million-20.80Increase in Short Interest
SMLR
Semler Scientific
1.2$108.24-0.2%$727.08 million$32.77 million76.23Insider Selling
Decrease in Short Interest
News Coverage
ViewRay logo
VRAY
ViewRay
1.3$4.43-2.9%$691.44 million$87.78 million-4.98
Stereotaxis logo
STXS
Stereotaxis
0.6$8.37-2.3%$603.35 million$28.90 million-76.09
Cutera logo
CUTR
Cutera
1.3$30.75-1.7%$556.07 million$181.71 million-16.99Gap Down
Zynex logo
ZYXI
Zynex
1.8$15.26-1.5%$523.87 million$45.47 million46.24
Edap Tms logo
EDAP
Edap Tms
1.3$9.02-1.9%$267.82 million$50.23 million-150.33Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.24-1.8%$195.07 million$3.38 million-4.31Decrease in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.20-2.9%$137.33 millionN/A0.00News Coverage
FONR
FONAR
1.1$18.00-0.2%$117.78 million$85.69 million16.98
IRIDEX logo
IRIX
IRIDEX
0.9$7.34-0.3%$113.61 million$43.45 million-13.35Gap Down
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.28-3.5%$98.18 million$10,000.00-1.24Analyst Upgrade
Increase in Short Interest
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.22-2.5%$94.87 millionN/A-1.61Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.80-2.2%$89.20 million$2.39 million-2.28Decrease in Short Interest
Gap Up
Electromed logo
ELMD
Electromed
1.8$10.09-0.0%$87.13 million$32.47 million24.02Analyst Downgrade
Gap Down
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.72-1.6%$40.28 million$1.50 million-1.01Increase in Short Interest
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10-90.1%$38.87 million$40,000.000.00Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.29-0.9%$31.63 million$5.51 million-0.11Increase in Short Interest
Gap Down
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.00-0.0%$31.03 million$6.57 million-0.01
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$4.40-2.3%$27.14 million$15.09 million0.00Gap Up
PEYE
Precision Optics
0.4$1.62-0.0%$21.49 million$9.92 million-16.20
STRR
Star Equity
0.1$3.19-3.4%$16.24 million$114.18 million-1.02
Vaso logo
VASO
Vaso
0.9$0.08-48.9%$15.14 million$75.75 million4.09High Trading Volume
News Coverage
Gap Up
GTHP
Guided Therapeutics
0.3$0.82-1.2%$10.81 million$40,000.00-3.42
Micron Solutions logo
MICR
Micron Solutions
0.3$3.15-10.5%$10.59 million$17.50 million22.50Increase in Short Interest
NIMU
Non-Invasive Monitoring Systems
0.5$0.03-0.0%$2.49 millionN/A0.00Upcoming Earnings
RSLSD
ReShape Lifesciences
0.4N/AN/A$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.09-6.4%$1.29 millionN/A6.06Gap Down
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55-0.0%$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05-0.0%$764,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01-0.0%$364,000.00N/A0.00Gap Up
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03-0.0%$356,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00-0.0%$265,000.00N/A0.00Decrease in Short Interest
News Coverage
ULGX
Urologix
0.6$0.01-0.0%$153,000.00N/A0.00Gap Up
AKSY
Aksys
0.0$0.00-0.0%$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.30-13.2%$0.00$9.40 million-5.04Increase in Short Interest
Gap Up
HRTT
Heart Tronics
0.0$0.15-0.0%$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.